Omeros Corporation(OMER)Earnings, Financials & Key RatiosOmeros Corporation (OMER) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash and equivalents have dwindled to a critical $1.9 million, which is insufficient to support ongoing clinical obligations and suggests a high risk of shareholder dilution.
Omeros Corporation (OMER) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Omeros Corporation (OMER) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.24vs $0.40+40.0% | $10Mvs $4M+136.4% |
| Q2 2026 | Mar 31, 2026 | $3.14vs $0.55+670.9% | —vs $2M |
| Q4 2025 | Nov 13, 2025 | $0.19vs $0.58+67.2% | — |
| Q3 2025 | Aug 14, 2025 | $0.53vs $0.55+3.6% | —vs $312,500 |
Recent stock market news and headlines for Omeros Corporation (OMER)
Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Medicines Agency's (EMA) expert panel has rejected its primary commercial asset.
The European Medicines Agency's Human Medicines Committee (CHMP) on Friday issued a negative opinion for Omeros Corp.'s (NASDAQ:OMER) narsoplimab.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with.
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.
Key metrics vs top competitors for Omeros Corporation (OMER)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.34 | $748.36M | -196.20 | — | — | — | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — | |
| $85.44 | $7.09B | 10.98 | 114.51% | -22.58% | — | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — |
Omeros Corporation (OMER) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Omeros Corporation (OMER) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Mar 31, 2026·SEC
Jan 7, 2026·SEC
Get notified when OMER posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Omeros Corporation (OMER) stock FAQ — growth, dividends, profitability & financials explained
Omeros Corporation (OMER) reported $9.9M in revenue for fiscal year 2025. This represents a 414% increase from $1.9M in 2007.
Yes, Omeros Corporation (OMER) is profitable, generating $86.2M in net income for fiscal year 2025 (871.0% net margin).
Omeros Corporation (OMER) had negative free cash flow of $94.8M in fiscal year 2025, likely due to heavy capital investments.
